ProCE Banner Activity

First-line HCVAD + Ponatinib Appears Superior to HCVAD + Dasatinib in Ph+ ALL

Slideset Download
Conference Coverage
This propensity score analysis comparing 2 phase II studies shows improved EFS and OS with addition of ponatinib vs dasatinib to standard HCVAD chemotherapy in newly diagnosed Ph+ ALL.

Released: June 13, 2016

Expiration: June 12, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals